Science ❯ Clinical research

Oncology clinical trials

EGFR-mutated NSCLC trials Phase 3 randomized controlled trials

FDA Approves Tecentriq With Chemotherapy for Stage III dMMR Colon Cancer

ATOMIC phase 3 data showing a halving of recurrence risk support a move to add immunotherapy to post‑surgery care for this molecular subgroup.

FDA Approves Tucatinib as Chemotherapy‑Free Maintenance for Advanced HER2‑Positive Breast Cancer

Two Combination Regimens Become NCCN‑Preferred First‑Line Options for EGFR‑Mutated Lung Cancer